Flashback Foreword: Activity of First-Line Trastuzumab

Abstract

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. March 15, 2023 JCO Flashback: Trastuzumab Monotherapy for HER2-Positive Breast Cancer (2002). March 15, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02843 Journal of Clinical Oncology - published online before print March 15, 2023 PMID: 36921334 Flashback Foreword: Activity of First-Line Trastuzumab Jennifer J. Griggs, MD, MPH1xJennifer J. GriggsSearch for articles by this author Show More 1Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02843 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2002, Vogel et al1 demonstrated that single-agent trastuzumab in people with human epidermal growth factor receptor 2–positive metastatic breast cancer yielded a response rate rivaling chemotherapy and a nonprogression rate of more than 50% at 12 months in people who had declined chemotherapy as first-line therapy. The effect of this trial was the demonstration of activity of single-agent trastuzumab in people with breast cancer who decline chemotherapy and to further illustrate the predictive importance of high levels of overexpression and overamplification of human epidermal growth factor receptor 2.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Activity of First-Line TrastuzumabThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jennifer J. GriggsEmployment: Anglona CorporationStock and Other Ownership Interests: Anglona CorporationNo other potential conflicts of interest were reported. Companion Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer JCO Flashback: Trastuzumab Monotherapy for HER2-Positive Breast Cancer (2002)